Loading clinical trials...
Loading clinical trials...
Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
LAVOUE
Rennes, France
Start Date
March 1, 2015
Primary Completion Date
March 1, 2020
Completion Date
March 1, 2020
Last Updated
August 17, 2021
13
ACTUAL participants
Cancer treatment
PROCEDURE
Lead Sponsor
Rennes University Hospital
NCT04550494
NCT05039801
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions